- Home
- HOLO vs PASG Comparison
HOLO vs PASG Comparison
Compare HOLO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- PASG
- Stock Information
- Founded
- HOLO 2018
- PASG 2017
- Country
- HOLO China
- PASG United States
- Employees
- HOLO N/A
- PASG N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- PASG Health Care
- Exchange
- HOLO Nasdaq
- PASG Nasdaq
- Market Cap
- HOLO 24.9M
- PASG 20.3M
- IPO Year
- HOLO N/A
- PASG 2020
- Fundamental
- Price
- HOLO $4.78
- PASG $6.95
- Analyst Decision
- HOLO
- PASG Strong Buy
- Analyst Count
- HOLO 0
- PASG 4
- Target Price
- HOLO N/A
- PASG $59.25
- AVG Volume (30 Days)
- HOLO 1.2M
- PASG 82.4K
- Earning Date
- HOLO 01-01-0001
- PASG 08-12-2025
- Dividend Yield
- HOLO N/A
- PASG N/A
- EPS Growth
- HOLO N/A
- PASG N/A
- EPS
- HOLO N/A
- PASG N/A
- Revenue
- HOLO $39,771,750.00
- PASG N/A
- Revenue This Year
- HOLO N/A
- PASG N/A
- Revenue Next Year
- HOLO N/A
- PASG N/A
- P/E Ratio
- HOLO N/A
- PASG N/A
- Revenue Growth
- HOLO 42.62
- PASG N/A
- 52 Week Low
- HOLO $4.16
- PASG $5.12
- 52 Week High
- HOLO $608.00
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- HOLO 46.73
- PASG 53.66
- Support Level
- HOLO $4.59
- PASG $5.51
- Resistance Level
- HOLO $5.67
- PASG $6.27
- Average True Range (ATR)
- HOLO 0.39
- PASG 0.66
- MACD
- HOLO 0.06
- PASG 0.19
- Stochastic Oscillator
- HOLO 36.43
- PASG 68.76
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.